Mitsugu Yamamoto - Concepedia

Author

Mitsugu Yamamoto

Hokkaido University Hospital

Also Known As

Mitsugu YAMAMOTO, Mitsugu Yamamoto

Publications

426

Citations

H-Index

Concepts

All Affiliations

Hokkaido University Hospital

About

Mitsugu Yamamoto is an author at Hokkaido University Hospital specializing in medicine, breast cancer, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	367
2	Obstetrics	3	3	132
3	Cell Biology	1	1	105
4	Endocrinology	1	1	45
5	Immunology	1	1	105

Mitsugu Yamamoto

Publications

414

Citations

H-Index

Page 1

	Year	Citations
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC) Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi, Breast Cancer Breast OncologyCancer ImmunosurveillanceDeath Ligand 1Therapeutic CandidateImmune Checkpoint Inhibitors	2017	105
Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer Tatsuya Yoshioka, Mitsuchika Hosoda, Mitsugu Yamamoto, Breast Cancer Breast OncologyMedicinePathologyBreast CancerCancer Treatment	2013	103
p53 accumulation is a strong predictor of recurrence in estrogen receptor‐positive breast cancer patients treated with aromatase inhibitors Mitsugu Yamamoto, Mitsuchika Hosoda, Kiichiroh Nakano, Cancer Science Endocrine OncologyBreast OncologyMedicineP53 AccumulationStrong Predictor	2013	76
Prognostic significance of pre-treatment neutrophil: lymphocyte ratio in Japanese patients with breast cancer. Kiichiroh Nakano, Mitsuchika Hosoda, Mitsugu Yamamoto, PubMed	2014	47
Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer Mitsuchika Hosoda, Mitsugu Yamamoto, Kiichiroh Nakano, Breast Cancer Research and Treatment Breast OncologyProgesterone ReceptorDifferential ExpressionHormonal ReceptorPathology	2014	45
Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis Naoki Niikura, Akihiko Shimomura, Yumi Fukatsu, Breast Cancer Research and Treatment Breast OncologyMedicineDurable Complete ResponsePathologyBreast Cancer	2017	27
Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience Naoko Ishida, Kazuhiro Araki, Takehiko Sakai, Breast Cancer Metastatic Breast CancerOncologyBreast OncologyGynecologyBreast Cancer	2015	11

Page 1